Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 17470.0
(0.81%)
KRW 17470.0
(0.81%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 126.39 Billion KRW | 33.68% |
| 2022 | 94.55 Billion KRW | 12.67% |
| 2021 | 83.92 Billion KRW | 7.21% |
| 2020 | 78.27 Billion KRW | 3.24% |
| 2019 | 75.81 Billion KRW | -8.91% |
| 2018 | 83.23 Billion KRW | -6.51% |
| 2017 | 89.03 Billion KRW | 2.0% |
| 2016 | 87.28 Billion KRW | 4.07% |
| 2015 | 83.87 Billion KRW | 4.3% |
| 2014 | 80.41 Billion KRW | -7.43% |
| 2013 | 86.87 Billion KRW | -4.39% |
| 2012 | 90.86 Billion KRW | -6.75% |
| 2011 | 97.43 Billion KRW | -1.03% |
| 2010 | 98.45 Billion KRW | 17.04% |
| 2009 | 84.11 Billion KRW | 6.26% |
| 2008 | 79.16 Billion KRW | 13.78% |
| 2007 | 69.57 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 30.74 Billion KRW | -1.71% |
| 2024 Q2 | 26.58 Billion KRW | -29.61% |
| 2023 Q4 | 31.28 Billion KRW | 229.06% |
| 2023 FY | 126.39 Billion KRW | 33.68% |
| 2023 Q1 | 22.08 Billion KRW | -28.89% |
| 2023 Q2 | -25.48 Billion KRW | -215.4% |
| 2023 Q3 | -24.23 Billion KRW | 4.89% |
| 2022 FY | 94.55 Billion KRW | 12.67% |
| 2022 Q3 | 25.32 Billion KRW | 2.11% |
| 2022 Q4 | 31.05 Billion KRW | 22.62% |
| 2022 Q1 | 20.87 Billion KRW | -8.95% |
| 2022 Q2 | 24.8 Billion KRW | 18.83% |
| 2021 Q2 | 20.74 Billion KRW | 12.19% |
| 2021 Q4 | 22.92 Billion KRW | 5.35% |
| 2021 Q3 | 21.76 Billion KRW | 4.9% |
| 2021 FY | 83.92 Billion KRW | 7.21% |
| 2021 Q1 | 18.49 Billion KRW | -15.56% |
| 2020 FY | 78.27 Billion KRW | 3.24% |
| 2020 Q1 | 16.98 Billion KRW | -18.11% |
| 2020 Q3 | 20.44 Billion KRW | 7.91% |
| 2020 Q4 | 21.89 Billion KRW | 7.11% |
| 2020 Q2 | 18.94 Billion KRW | 11.54% |
| 2019 Q1 | 16.99 Billion KRW | -12.35% |
| 2019 Q2 | 19.09 Billion KRW | 12.33% |
| 2019 Q4 | 20.74 Billion KRW | 9.21% |
| 2019 FY | 75.81 Billion KRW | -8.91% |
| 2019 Q3 | 18.99 Billion KRW | -0.52% |
| 2018 Q4 | 19.38 Billion KRW | -5.49% |
| 2018 FY | 83.23 Billion KRW | -6.51% |
| 2018 Q3 | 20.51 Billion KRW | -6.66% |
| 2018 Q2 | 21.97 Billion KRW | 2.91% |
| 2018 Q1 | 21.35 Billion KRW | -7.95% |
| 2017 Q1 | 21.6 Billion KRW | -10.52% |
| 2017 Q2 | 22.21 Billion KRW | 2.85% |
| 2017 Q3 | 22.01 Billion KRW | -0.9% |
| 2017 FY | 89.03 Billion KRW | 2.0% |
| 2017 Q4 | 23.2 Billion KRW | 5.38% |
| 2016 Q4 | 24.14 Billion KRW | 17.67% |
| 2016 Q1 | 21.06 Billion KRW | -10.98% |
| 2016 FY | 87.28 Billion KRW | 4.07% |
| 2016 Q2 | 21.57 Billion KRW | 2.43% |
| 2016 Q3 | 20.51 Billion KRW | -4.9% |
| 2015 Q4 | 23.65 Billion KRW | 12.91% |
| 2015 Q2 | 19.58 Billion KRW | -0.44% |
| 2015 FY | 83.87 Billion KRW | 4.3% |
| 2015 Q3 | 20.95 Billion KRW | 6.99% |
| 2015 Q1 | 19.67 Billion KRW | -2.0% |
| 2014 Q2 | 18.67 Billion KRW | -11.32% |
| 2014 Q1 | 21.05 Billion KRW | -10.98% |
| 2014 FY | 80.41 Billion KRW | -7.43% |
| 2014 Q4 | 20.07 Billion KRW | -2.6% |
| 2014 Q3 | 20.6 Billion KRW | 10.37% |
| 2013 Q3 | 22.76 Billion KRW | 8.26% |
| 2013 FY | 86.87 Billion KRW | -4.39% |
| 2013 Q2 | 21.02 Billion KRW | 8.23% |
| 2013 Q1 | 19.42 Billion KRW | -12.84% |
| 2013 Q4 | 23.65 Billion KRW | 3.92% |
| 2012 Q1 | 23.12 Billion KRW | -22.5% |
| 2012 Q2 | 21.32 Billion KRW | -7.79% |
| 2012 Q3 | 24.11 Billion KRW | 13.11% |
| 2012 Q4 | 22.29 Billion KRW | -7.57% |
| 2012 FY | 90.86 Billion KRW | -6.75% |
| 2011 Q4 | 29.83 Billion KRW | 12.02% |
| 2011 Q1 | 23.08 Billion KRW | -19.53% |
| 2011 Q2 | 17.88 Billion KRW | -22.54% |
| 2011 FY | 97.43 Billion KRW | -1.03% |
| 2011 Q3 | 26.63 Billion KRW | 48.96% |
| 2010 FY | 98.45 Billion KRW | 17.04% |
| 2010 Q2 | 25.27 Billion KRW | 12.76% |
| 2010 Q3 | 22.08 Billion KRW | -12.62% |
| 2010 Q1 | 22.41 Billion KRW | -6.19% |
| 2010 Q4 | 28.68 Billion KRW | 29.92% |
| 2009 Q3 | 20.38 Billion KRW | -1.16% |
| 2009 Q4 | 23.89 Billion KRW | 17.22% |
| 2009 Q1 | 19.22 Billion KRW | -6.28% |
| 2009 FY | 84.11 Billion KRW | 6.26% |
| 2009 Q2 | 20.62 Billion KRW | 7.25% |
| 2008 Q3 | 21.35 Billion KRW | 15.41% |
| 2008 Q4 | 20.51 Billion KRW | -3.94% |
| 2008 FY | 79.16 Billion KRW | 13.78% |
| 2008 Q1 | 18.78 Billion KRW | -1.47% |
| 2008 Q2 | 18.5 Billion KRW | -1.47% |
| 2007 Q1 | 14.85 Billion KRW | 0.0% |
| 2007 Q3 | 18.8 Billion KRW | 11.67% |
| 2007 Q2 | 16.84 Billion KRW | 13.35% |
| 2007 FY | 69.57 Billion KRW | 0.0% |
| 2007 Q4 | 19.06 Billion KRW | 1.36% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -81.943% |
| Yuhan Corporation | 489.94 Billion KRW | 74.203% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -167.476% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 54.607% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 57.585% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 47.096% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 47.096% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 63.961% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -215.563% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 34.736% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -82.613% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -115.525% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 43.066% |
| Boryung Corporation | 285.16 Billion KRW | 55.677% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 27.422% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 49.265% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -75.586% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -90.301% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -35.105% |
| CKD Bio Corp. | 25.19 Billion KRW | -401.644% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -68.413% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 69.071% |
| Yuhan Corporation | 489.94 Billion KRW | 74.203% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 1.0% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -167.476% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -10.17% |
| HANDOK Inc. | 153.76 Billion KRW | 17.803% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 58.824% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 79.313% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -202.451% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -125.572% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -167.476% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -197.593% |
| JW Holdings Corporation | 301.25 Billion KRW | 58.045% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 51.565% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 47.096% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -85.026% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -92.228% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 27.745% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 77.447% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 1.0% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -6.919% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 23.451% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -44.38% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 27.422% |
| JW Lifescience Corporation | 20.26 Billion KRW | -523.806% |